A Nielsen Holdings PLC executive spoke at a conference about how proposed Treasury Department tax rules could raise the company's tax rate. A Business News article Thursday about the rules incorrectly implied the company has raised its concerns with the U.S. government.

The wholesale acquisition cost of the prostate cancer drug Xtandi, marketed by Astellas Pharma Inc. of Japan and Medivation Inc., is about $9,400 a month, compared with about $8,600 for rival drug Zytiga from Johnson & Johnson. A Business News article Thursday about a test that can identify patients unlikely to benefit from either drug quoted Xtandi's price as more than $10,000, using the average wholesale price, which is higher than the wholesale acquisition cost.

(END) Dow Jones Newswires

July 09, 2016 02:47 ET (06:47 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Astellas Pharma (PK) (USOTC:ALPMY)
過去 株価チャート
から 4 2024 まで 5 2024 Astellas Pharma (PK)のチャートをもっと見るにはこちらをクリック
Astellas Pharma (PK) (USOTC:ALPMY)
過去 株価チャート
から 5 2023 まで 5 2024 Astellas Pharma (PK)のチャートをもっと見るにはこちらをクリック